Abstract
Dysfunctioning of corticotropin-releasing factor (CRF) and its receptors (CRF1 and CRF2) has been linked to the development of stress-related disorders, such as affective disorders and drug abuse. The molecular characterization of CRF1 and CRF2 receptors and their splice variants has generated detailed information on their pharmacology, tissue distribution and physiology. In addition, the recent development of a small molecule CRF1 antagonist has provided important information on the contribution of this receptor to the development of stress-related diseases. Despite the high homology to the CRF1 receptor and the generation of peptide-based research tools, the physiological role of the CRF2 receptor is largely unclear. This is due to different expression patterns in rodents and primates and the lack of brainpenetrant CRF2-selective small molecule antagonists. However, the CRF2 receptor may be important for motivational types of behavior essential for survival, such as feeding and defense and impacts on cardiovascular function.
Keywords: stress-related disorders, drug abuse, depression, anxiety, CRF2, CRF1
CNS & Neurological Disorders - Drug Targets
Title: Corticotropin-Releasing Factor Receptor Antagonists in Affective Disorders and Drug Dependence - An Update
Volume: 5 Issue: 2
Author(s): Frank M. Dautzenberg and Thomas Steckler
Affiliation:
Keywords: stress-related disorders, drug abuse, depression, anxiety, CRF2, CRF1
Abstract: Dysfunctioning of corticotropin-releasing factor (CRF) and its receptors (CRF1 and CRF2) has been linked to the development of stress-related disorders, such as affective disorders and drug abuse. The molecular characterization of CRF1 and CRF2 receptors and their splice variants has generated detailed information on their pharmacology, tissue distribution and physiology. In addition, the recent development of a small molecule CRF1 antagonist has provided important information on the contribution of this receptor to the development of stress-related diseases. Despite the high homology to the CRF1 receptor and the generation of peptide-based research tools, the physiological role of the CRF2 receptor is largely unclear. This is due to different expression patterns in rodents and primates and the lack of brainpenetrant CRF2-selective small molecule antagonists. However, the CRF2 receptor may be important for motivational types of behavior essential for survival, such as feeding and defense and impacts on cardiovascular function.
Export Options
About this article
Cite this article as:
Dautzenberg M. Frank and Steckler Thomas, Corticotropin-Releasing Factor Receptor Antagonists in Affective Disorders and Drug Dependence - An Update, CNS & Neurological Disorders - Drug Targets 2006; 5 (2) . https://dx.doi.org/10.2174/187152706776359619
DOI https://dx.doi.org/10.2174/187152706776359619 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Endothelium and Platelets in Cardiovascular Disease: Potential Targets for Therapeutic Intervention
Current Medicinal Chemistry - Cardiovascular & Hematological Agents The Use of Antiparkinsonian Agents in the Management of Drug-Induced Extrapyramidal Symptoms
Current Pharmaceutical Design Is Nitric Oxide Assuming a Janus-Face in The Central Nervous System?
Current Medicinal Chemistry Recent Advances in the Management of Pulmonary Arterial Hypertension
Current Respiratory Medicine Reviews Natriuretic Peptide Guided Heart Failure Management
Current Clinical Pharmacology Towards the Development of Tumor Necrosis Factor (TNF) Sensitizers:Making TNF Work Against Cancer
Current Pharmaceutical Design Value of Carnitine Therapy in Kidney Dialysis Patients and Effects on Cardiac Function from Human and Animal Studies
Current Drug Targets Nitric Oxide: News from Stem Cells to Platelets
Current Medicinal Chemistry Influence of Drugs on Mild Cognitive Impairment in Parkinson’s Disease: Evidence from the PACOS Study
Current Neuropharmacology Novel Therapeutic Targets for Phosphodiesterase 5 Inhibitors: current state-of-the-art on systemic arterial hypertension and atherosclerosis
Current Pharmaceutical Biotechnology Thrombotic Thrombocytopenic Purpura, from the Perspectives of a Pediatrician
Current Pediatric Reviews Adrenoceptors: Non Conventional Target for Breast Cancer?
Current Medicinal Chemistry Caring for HIV-Infected Patients in the ICU in The Highly Active Antiretroviral Therapy Era
Current HIV Research Role of Iron Deficiency and Overload in the Pathogenesis of Diabetes and Diabetic Complications
Current Medicinal Chemistry Current HIV Treatment Guidelines - An Overview
Current Pharmaceutical Design Pharmacotherapy of Persons with Dementia in Long-term Care in Australia: A Descriptive Audit of Central Nervous System Medications
Current Drug Safety Coumarins as Promising Scaffold for the Treatment of Age-related Diseases – An Overview of the Last Five Years
Current Topics in Medicinal Chemistry The Interactions of Anticancer Agents with Tea Catechins: Current Evidence from Preclinical Studies
Anti-Cancer Agents in Medicinal Chemistry Antisense Therapy for Cardiovascular Diseases
Current Pharmaceutical Design Subject Index to Volume 10
Current Medicinal Chemistry